Cutibacterium granulosum

(aka Propionibacterium granulosum)

Bacteria
General | Carbohydrate O/F | Substrate utilisation | Enzymes | Metabolites | Antibiotics

Overview

  • Cutibacterium granulosum, (aka Propionibacterium granulosum), is a Gram-positive, non-spore-forming, anaerobic, rod-shaped bacterium. It has been detected in at least 7 gut microbiome compilation studies or metastudies. Cutibacterium granulosum is probably a common, although minor, coloniser of the gut. (Dekio2020; Scholz2016)



  • This organism has been recovered from human faeces. The risk classification (www.baua.de) for this organism is 2, i.e., risk of individual infection, but low risk of spread (notes: human and animal pathogen). It is an opportunistic pathogen. A possible gut commensal.
    • GENERAL CHARACTERISTICS (Scholz2016);
    Character Response
  • Active enzymes:
  • hyaluridonase;
    • RESPONSE TO ANTIBIOTICS (Goldstein2003); (Tyrrell2012); (Snydman2008); (Goldstein2006d); (Goldstein2005); (Citron2003); (Goldstein2003a);
    Class Active Resistant
  • Penicillins:
  • amoxicillin-clavulanic acid; ampicillin; ampicillin-sulbactam; doripenem; ertapenem; imipenem; meropenem; penicillin; penicillin G; piperacillin-tazobactam;
  • Cephalosporins:
  • cefoxitin; cefuroxime;
  • Macrolides:
  • clarithromycin; erythromycin; pristinamycin; quinupristin-dalfopristin; telithromycin;
  • Quinolines:
  • gatifloxacin; levofloxacin; moxifloxacin;
  • Polypep/ketides:
  • bacitracin;
  • Heterocycles:
  • co-trimoxazole; metronidazole;
  • Vancomycins:
  • vancomycin; dalbavancin; teicoplanin;
  • Miscellaneous antibiotics:
  • clindamycin; daptomycin; linezolid; pristinamycin; telithromycin;

  • Finegold, S. M., Howard, R. A., & Vera, L. S. (1974). Effect of diet on human intestinal fecal flora: comparison of Japanese and American diets. Am. J. Clin. Nutr, 27, 1456–1469.

    • Details

    GENERAL
    Lineage Physiology General Growth Tolerances Hydrol./digest./degr.
    Phylum:  Actinobacteria Class:  Actinomycetia Order:  Propionibacteriales Family:  Propionibacteriaceae Genus:  Cutibacterium Alt. name:  Propionibacterium granulosum Gram stain:  + O2 Relation.:  anaerobic Spore:  No spore Morphology:  Rod
    Health:  Unknown
    Source:  human faeces
    ENZYME ACTIVITY
    Enzymes: General Enzymes: Carbohydrate Enzymes: Protein Enzymes: Arylamidases Enzymes: Esters/fats
    Hyaluridonase:  +
    ANTIBIOTICS ℞
    Penicillins & Penems (μg/mL) Cephalosporins (μg/mL) Aminoglycosides (μg/mL) Macrolides (μg/mL) Quinolones (μg/mL)
    Augmentin:  S(MIC50): 0.06, MIC90: 0.25, RNG: (0.03–0.25)
    ampicillin:  S(MIC50): 0.06, MIC90: 0.06, RNG: (0.03-0.5)
    amp-sulb:  S(MIC50): 0.25, MIC90: 0.5, RNG: (0.06–0.25)
    penicillin:  S(MIC50): 0.06, MIC90: 0.125, RNG: (0.02-0.125)
    penicillin_G:  S(MIC50): 0.06, MIC90: 0.125, RNG: (0.015–0.125)
    piper-taz:  S(MIC50): ≤0.03, MIC90: ≤0.03, RNG: (≤0.03-1)
    doripenem:  S(MIC50): 0.06, MIC90: 0.06, RNG: (0.06–0.06)
    ertapenem:  S(MIC50): 0.06, MIC90: 0.25, RNG: (0.06–0.25)
    imipenem:  S(MIC50): ≤0.03, MIC90: ≤0.03, RNG: (≤0.03-0.06)
    meropenem:  S(MIC50): 0.06, MIC90: 0.25, RNG: (0.06–0.25)
    cefoxitin:  S(MIC50): 0.25, MIC90: 2, RNG: (0.03–2)
    cefuroxime:  S(MIC50): 0.5, MIC90: 1, RNG: (0.25–8)
    erythromycin:  S(MIC50): 0.06, MIC90: 0.125, RNG: (0.06-0.125)
    clarithromycin:  S(MIC50): 0.03, MIC90: 0.03, RNG: (0.03)
    pristinamycin:  S(MIC50): 0.03, MIC90: 0.03, RNG: (0.03)
    quin-dalf:  S(MIC50): 0.06, MIC90: 0.2, RNG: (0.06-0.25)
    telithromycin:  S(MIC50): 0.03, MIC90: 0.03, RNG: (0.03)
    linezolid:  S(MIC50): 0.5, MIC90: 1, RNG: (0.25-1)
    gatifloxacin:  S(MIC50): 0.125, MIC90: 0.25, RNG: (0.125–0.25)
    levofloxacin:  S(MIC50): 0.25, MIC90: 0.5, RNG: (0.125–0.5)
    moxifloxacin:  S(MIC50): 0.25, MIC90: 0.5, RNG: (0.25–4)
    Tetracyclines (μg/mL) Vancomycin Class (μg/mL) Polypep/ketides (μg/mL) Heterocycles (μg/mL) Other (μg/mL)
    tetracycline:  Var(MIC50): 1, MIC90: 2, RNG: (1-4)
    dalbavancin:  S(MIC50): 0.25, MIC90: 0.5, RNG: (0.03-0.5)
    teicoplanin:  S(MIC50): 0.5, MIC90: 1, RNG: (0.125–1)
    vancomycin:  S(MIC50): 0.5, MIC90: 1, RNG: (0.5-1)
    bacitracin:  S(MIC50): 0.25, MIC90: 4, RNG: (0.25–4)
    metronidazole:  R(MIC50): >32, MIC90: >32, RNG: (8->32)
    co-trimoxazole:  R(MIC50): >8, MIC90: >8, RNG: (8->8)
    clindamycin:  S(MIC50): 0.015, MIC90: 0.03, RNG: (≤0.015-0.03)
    daptomycin:  S(MIC50): 0.5, MIC90: 2, RNG: (0.125-2)

    References

    SPECIFIC REFERENCES FOR CUTIBACTERIUM GRANULOSUM
  • Goldstein2003 - In Vitro Activities of Daptomycin, Vancomycin, Quinupristin- Dalfopristin, Linezolid, and Five Other Antimicrobials against 307 Gram-Positive Anaerobic and 31 Corynebacterium Clinical Isolates.
  • Dekio2020 - Cutibacterium modestum sp. nov., isolated from meibum of human meibomian glands, and emended descriptions of Cutibacterium granulosum and Cutibacterium namnetense.
  • Scholz2016 - The natural history of cutaneous propionibacteria, and reclassification of selected species within the genus Propionibacterium to the proposed novel genera Acidipropionibacterium gen. nov., Cutibacterium gen. nov. and Pseudopropionibacterium gen. nov.
  • Cassir2015 - Clostridium butyricum Strains and Dysbiosis Linked to Necrotizing Enterocolitis in Preterm Neonates
  • Hynes2000 - Hyaluronidases of Gram-positive bacteria.
  • Tyrrell2012 - In vitro activity of TD-1792, a multivalent glycopeptide-cephalosporin antibiotic, against 377 strains of anaerobic bacteria and 34 strains of Corynebacterium species.
  • Snydman2008 - In vitro activities of doripenem, a new broad-spectrum carbapenem, against recently collected clinical anaerobic isolates, with emphasis on the Bacteroides fragilis group.
  • Goldstein2006d - Comparative in vitro activities of retapamulin (SB-275833) against 141 clinical isolates of Propionibacterium spp., including 117 P. acnes isolates.
  • Goldstein2005 - Comparative in vitro activities of XRP 2868, pristinamycin, quinupristin-dalfopristin, vancomycin, daptomycin, linezolid, clarithromycin, telithromycin, clindamycin, and ampicillin against anaerobic gram-positive species, actinomycetes, and lactobacilli.
  • Citron2003 - In vitro activities of ramoplanin, teicoplanin, vancomycin, linezolid, bacitracin, and four other antimicrobials against intestinal anaerobic bacteria.
  • Goldstein2003a - In vitro activities of ABT-492, a new fluoroquinolone, against 155 aerobic and 171 anaerobic pathogens isolated from antral sinus puncture specimens from patients with sinusitis.
  • ...............................
    • GUT MICROBIOME COMPILATIONS AND METASTUDIES FOR CUTIBACTERIUM GRANULOSUM
  • Cassir2015 - Clostridium butyricum Strains and Dysbiosis Linked to Necrotizing Enterocolitis in Preterm Neonates
  • Dubourg2013 - The gut microbiota of a patient with resistant tuberculosis is more comprehensively studied by culturomics than by metagenomics.
  • Lagier2016 - Culture of previously uncultured members of the human gut microbiota by culturomics.
  • McLaughlin2010 - The bacteriology of pouchitis: a molecular phylogenetic analysis using 16S rRNA gene cloning and sequencing.
  • PerezBrocal2015 - Metagenomic Analysis of Crohn's Disease Patients Identifies Changes in the Virome and Microbiome Related to Disease Status and Therapy, and Detects Potential Interactions and Biomarkers
  • RajilicStojanovic2014 - The first 1000 cultured species of the human gastrointestinal microbiota.
  • Yang2020 - Species-Level Analysis of Human Gut Microbiota With Metataxonomics.
  • Yang2020a - Establishing high-accuracy biomarkers for colorectal cancer by comparing fecal microbiomes in patients with healthy families
  • ...............................
    • Added: April 08, 2021